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Abstract
Background: Open Science is ‘the movement to make scientific research, data and dissemination accessible to all
levels of an inquiring society’.
In the spirit of the Open Science movement, advance publication of protocols for clinical trials is now being advocated
by BioMed Central, BMJ Open and others. Simultaneously, participants are becoming increasingly active in their pursuit
and sharing of trial- and health- related information. Whilst access to protocols alongside published trial findings has
clear benefits, advance publication of trial protocols is potentially problematic for trials of complex behavioural
interventions. In this article we explain, with examples, how this could lead to unblinding, ‘contamination’ between
intervention and control groups and deliberate biasing of assessment outcomes by participants. We discuss potential
solutions and demonstrate the need for public debate about how this issue is best managed.
Conclusion: Triallists may still be underestimating participants’ interest in information. This needs to change: joint and
open discussions with the public are needed to inform how we should proceed.
Keywords: Open Science, Complex interventions, Protocols, Behaviour change, Therapy interventions, Clinical trials,
E-Health, Advance publication, Trial registration, Codesign
Background
Open Science is ‘the movement to make scientific
research, data and dissemination accessible to all levels
of an inquiring society’ [1]. In the spirit of the Open
Science movement, advance publication of protocols for
clinical trials is now being advocated by BioMed Central,
BMJ Open and others. Simultaneously, participants are
becoming increasingly active in their pursuit and sharing
of trial- and health-related information. For the vast ma-
jority of trials this is a good thing: access to well-written
protocols alongside published trial findings has clear
benefits [2, 3], including the provision of more informa-
tion than that available in trial registries. Advance
publication of protocols is also about transparency so
that post-trial publications are consistent (in process and
analysis) or have to have account for protocol deviations.
A good protocol must specify all interventions in
detail, so that they are replicable [4]. For novel or expen-
sive drug interventions or those involving devices, lack
of access to the intervention outside the trial arm limits
the possibility of contamination even if the details are
fully available in the protocol. However, a published
protocol makes other interventions, such as a fully
described therapy or self-administered lifestyle change,
accessible outside of the trial context. The resulting
problems could include unblinding, ‘contamination’ be-
tween intervention and control groups and deliberate
biasing of assessment outcomes by participants. We
discuss examples and demonstrate the need for public
debate about how this issue is best managed.
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Potential for unblinding and contamination
An interesting example of the potential difficulties faced
with published protocols is that of Eliasson et al. [5].
Their paper sets out the protocol for a randomised con-
trolled trial comparing a form of modified constraint
therapy (baby-CIMT) versus massage for infants at risk
of developing unilateral cerebral palsy. Both approaches
are described in detail. The hypotheses are that the
baby-CIMT group will develop manual ability in the in-
volved hand faster than the massage group and that
these differences will remain at the age of 2 years;
additionally, that parents in the baby-CIMT group will
feel more competent about parenting. The protocol also
states that parents will be blinded to the study hypoth-
eses but not to the group allocation – clearly this will
not be the case for parents who have accessed the pub-
lished protocol, which may alter their engagement with
the trial. This could be a particular problem for partici-
pants who discover in this way that they are in the con-
trol group. Parents may be provoked to change their
behaviour and seek the active intervention for their
child, given that clinical benefit is a major item on par-
ental agendas when entering trials [6–8]. Unblinding
and contamination due to patients allocated to placebo
becoming aware of the nature of a therapy intervention
being received by other nearby patients is an ongoing
problem [9]. Though we are not aware of examples
where this has occurred due to patients accessing the
published protocol, it is a theoretical risk. Furthermore,
parents of newborn infants allocated to the control
group in a recent unblinded randomised controlled trial
showed an ‘almost universal experience of disappoint-
ment’, with a few admitting either an attempt or success
in obtaining the treatment outside of the trial context
[10]. This latter behaviour has been described as ‘com-
pensatory rivalry’ by Cook and Campbell [11].
We contacted the authors of the baby-CIMT paper
[5]; they were not aware of any parents having accessed
the online protocol but this was not a focus of their in-
vestigation. Interestingly, the protocol was published
relatively late into the data collection period (trial start
date September 2012; protocol publication date June
2014; study completion date December 2015); this may
have been a protective factor.
Biasing of assessment outcomes
Access to the published protocol also gives participants
the opportunity to prepare for assessments in order to
influence their outcome. We first identified this as a
genuine risk when we undertook a focus group to dis-
cuss the details of a planned pilot feasibility study. One
of the suggested questionnaires (Parenting Sense of
Competence Scale [12]) required the parent to indicate
on a five-point scale the extent to which they agreed or
disagreed with each of a series of statements. One parent
commented that it reminded her of her experiences with
the Edinburgh Postnatal Depression Scale [13] after she
had had her second child. Specifically, she had ‘Googled’
the scale and prepared her answers prior to her visit
from the health visitor in order to avoid being identified
as having possible depression (see Table 1). She was not
the only parent who commented that they might give
misleading responses to questions in order to avoid ex-
posing vulnerabilities. Whilst not singled out by the
Cochrane Collaboration as a specific form of bias [14],
we think that manipulation of assessment outcomes by
participants merits further investigation. The Cochrane
Collaboration describes detection bias, in which there
are differences between the intervention and control
groups with respect to outcome assessment due to
knowledge of the assessor about treatment assignment.
We describe a different situation, in which knowledge of
the nature of the assessment by the participant could
lead to a deliberate alteration of their response. In es-
sence it represents a potential form of response bias
[15], i.e. ‘a systematic tendency to respond to a range of
questionnaire items on some basis other than the spe-
cific item content’.
Is this really a new problem?
Some of the issues we describe have been seen in other
contexts for a long time. It comes as no surprise that
study participants might alter behaviours which they
know or suspect are being monitored. In the field of ex-
perimental psychology, such effects are covered by the
term ‘demand characteristics’, defined as ‘the totality of
cues and mutual expectations which inhere in a social
context … which serve to influence the behaviour and/
or self-reported experience of the research receiver’ [16];
though caution has been advocated in using this term
outwith the laboratory setting [17], with the broader
term ‘research participation effects’ preferred [18]. What
Table 1 Biassing of assessment outcomes: example from a
codesign workshop
Emma: ‘To be honest, like, I, from my experience, and I had a really hard
time after Edgar was born, my second one. And, erm, had to fill in
Edinburgh thing.’
Anna: ‘Yeah, the depression thing, yeah.’
Emma: ‘Yeah, and I totally, like, filled it in ‘cause I didn’t want to have
depression (laughter), so like, I like, I Googled it and everything, you
know, to see what score you needed. (Laughter) and, erm.‘
Anna: ‘Wow.’
Emma: ‘Well no, I Goo- ‘cause you can do it online can’t you? And then
I came up with like 12.5 or something and you needed 11 to not have
depression, so I was like… And then the health visitor came round so I
was thinking, “Right, 11” …’
(Participant names have been changed to respect confidentiality)
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is new is the extent to which these problems scale up in
the shift towards increasingly accessible information, in-
creasingly early in the timeline of ongoing research. It is
now easy to seek out detailed information on the nature
of many assessment tools on the Internet, potentially in-
fluencing performance in those assessments.
How big could the problem be?
It is easy to look up a study protocol; many are pub-
lished in open access journals and are freely available. In
2015 over 80% of the developed world (and over one
third of the developing world) had Internet access at
home [19]. Use of the Internet to obtain health-related
information is now the norm [20], so there is nothing to
stop participants from accessing published protocols on-
line. Such information is likely to be shared more widely
through the use of social media [21] and online patient
communities [22]. Information about previous similar
trials (either from academic journals or reports in the
news or social media) may also influence the under-
standing and behaviour of participants.
Participants can potentially determine which trial arm
they are in, and choose to follow instructions related to
items from any trial arm (or none), based on their un-
derstanding of the stated hypotheses. Whilst Information
Sheets could also prompt similar behaviours, the infor-
mation in the published protocol is more detailed, yet
often appears to be written with the assumption that it
will not be read by participants. This adds to the prob-
lem because there is an additional risk that the accessed
information may be misinterpreted in a wide range of
ways. However, we simply do not know the degree to
which these factors currently impact on clinical trials of
behavioural change interventions. This compounds the
existing problem that adherence to behavioural change
interventions is often low even in the absence of other
considerations [23].
To declare that advance publication of protocols for
certain trial types could bias outcomes may seem a step
in the wrong direction, but to deny the potential prob-
lem is foolish. At the moment, the cast of characters
who might engage with published protocols is still seen
as editors, funders, researchers and reviewers, all actively
involved for good scientific reasons. Two other more
opaque figures remain, namely readers and patients.
Currently, patients are configured as users of this infor-
mation in a specific way, as ‘prospective volunteers’ seek-
ing information about potential trials to take part in. If
we also see them as part of the category of reader, they
may also be ‘citizen scientists’ who are now empowered
to discovering deviations in protocols. However, they
can also engage with this information in alternate ways,
as ‘participants in trials’ or as relatives or friends of those
taking part in trials. This last form of engagement is in
some ways the most problematic for ongoing trials. If
the patients are prospective volunteers then the protocol
could supplement the Information Sheet and help them
to decide whether to enter the trial. It could also influ-
ence their conduct when they enter the trial. If, instead,
they are already taking part in the trial and subsequently
access the protocol and change their behaviour, the trial
data will be affected. Participants could also be con-
cerned or even angry that certain information was with-
held. Maximising the quality of the Information Sheets
provided to participants may avoid this to some extent.
However, with full transparency it becomes impossible
to undertake randomised controlled trials with blinding
of participants for certain types of complex intervention.
A way forward?
It would be interesting to ask participants to what extent
they or their significant others sought information re-
garding their trial beyond that provided by the research
team, what they gleaned and whether it influenced their
behaviour in relation to the trial. Assuming that partici-
pants have good memories and a willingness to share
such information, this could help us to understand the
current scale of the problem.
If published protocols are found to influence the be-
haviour of participants in complex intervention trials,
trial preregistration with embargoed preregistration of
the detailed protocol until trial completion may be the
best option. This solution is already available – protocols
registered on the Open Science Framework can be em-
bargoed for up to 4 years before they are published. The
embargo limit is key in avoiding publication bias or even
covert registration of multiple protocols.
Another potential solution is the Registered Reports
initiative [24]. This provides the opportunity to submit a
detailed research proposal to a journal for peer review,
including methods and planned analyses, prior to com-
mencing the research. The journal can then provisionally
agree in advance to publish the final study. This practice
could encourage high standards of research integrity
whilst keeping the protocol under wraps until the study
is complete.
Trial preregistration, that requires declaration of the
primary outcome measure in advance, has probably con-
tributed to a recent increase in reported null effects in
clinical trials [25] and could also help reduce duplication
of research efforts even without a full published
protocol. The complex intervention descriptions on trial
preregistration websites probably lack the detail needed
to allow replication of trial behaviours – but the prob-
lems of unblinding and biasing of assessment outcomes
could still occur. Trial preregistration also helps protect
the integrity of published research: one of the authors
(AB) has had experience of discovering serious
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unexplained deviations from the protocol in a submitted
paper based on trial registration details alone. However,
published reports of trials have not infrequently deviated
in significant and unexplained ways from published
registry entries, though similar deviations from pub-
lished protocols are also reported [26, 27].
What advantages of advance protocol publication do we
risk losing in this field? Looking at the statement from
BMJ Open [28], advance publication is about ‘enabling re-
searchers and funding bodies to stay up to date in their
fields’, preventing duplication of work and facilitating
collaboration. Arguably, trial preregistration data would
suffice for these purposes, whilst reducing the contamin-
ation risk and still allowing potential participants to search
for studies for which they may be eligible. Alternatively,
published protocols will have to be written with the
expectation that they may be accessed by participants (or
members of their social circle), in which case we can ex-
pect to encounter the problems described above, making
it extremely hard or impossible to undertake certain types
of trial. Given the calls for more comprehensive reporting
of all the stages of the development of complex interven-
tions [29] alongside the development of reporting guide-
lines for these stages [30], similar problems can be
predicted with papers describing the development of the
content and delivery of interventions.
The onus is now on researchers to smarten up experi-
mental designs to deal with these potential problems.
Objective tracking of adherence, for example, through
smartphone data, is one approach. Researchers could
also draw up contracts with participants whereby they
agree not to attempt to unblind themselves through the
use of the Internet or social media. This approach could
of course backfire by providing a more explicit list of
unblinding options for those hungry for information.
Conclusions
The Open Science movement has emerged alongside the
rise of more active, engaged, patients and is here to stay.
It has furthered the drive for increased research trans-
parency which is overall extremely beneficial. As part of
this drive, advanced publication of trial protocols is ad-
vocated, with a full description of interventions. This
causes difficulties for trials of complex behavioural
change interventions, such as unblinding, contamination
and biasing of questionnaire-based assessments. Trial-
lists may still be underestimating the public, and espe-
cially participants’ interest in information [22]. This
needs to change: joint and open discussions with the
public are needed to inform how we should proceed as
there is currently no optimal solution.
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